Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 14.8

De Novo Posttransplant Solid Malignancy, 2000 to 2009

Liver Recipients

Malignancies by Type Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Total # of Post-Tx Malignancies 415 397 443 393 420 474 397 253 165 88
Squamous/Basal Cell Carcinoma 197 167 171 147 156 191 135 90 52 32
Melanoma 5 9 16 13 7 16 11 9 2 3
Kaposi Sarcoma 2 1 3 - 1 - - 2 - -
Central Nervous System 2 3 4 3 4 3 7 6 2 4
Genito-Urinary (1) 42 47 39 45 38 41 35 22 15 1
Gastro-Intestinal (2) 43 38 41 51 48 46 46 23 21 7
Primary Hepatic Tumor 18 12 23 18 22 32 18 18 13 8
Metastatic Hepatic Tumor 9 13 17 13 24 24 20 13 7 2
Larynx/Bronchi/Lung 47 51 66 49 71 61 68 34 22 11
Breast/Thyroid 15 19 16 16 11 16 17 7 4 2
Leukemia 4 1 2 5 7 4 1 3 - -
Sarcoma (3) 1 - 3 3 2 2 - 3 1 1
Other 25 27 38 26 26 36 34 22 26 16
Unknown 5 9 4 4 3 2 5 1 - 1
Squamous/Basal Cell Carcinoma 47.5% 42.1% 38.6% 37.4% 37.1% 40.3% 34.0% 35.6% 31.5% 36.4%
Melanoma 1.2% 2.3% 3.6% 3.3% 1.7% 3.4% 2.8% 3.6% 1.2% 3.4%
Kaposi Sarcoma 0.5% 0.3% 0.7% - 0.2% - - 0.8% - -
Central Nervous System 0.5% 0.8% 0.9% 0.8% 1.0% 0.6% 1.8% 2.4% 1.2% 4.5%
Genito-Urinary (1) 10.1% 11.8% 8.8% 11.5% 9.0% 8.6% 8.8% 8.7% 9.1% 1.1%
Gastro-Intestinal (2) 10.4% 9.6% 9.3% 13.0% 11.4% 9.7% 11.6% 9.1% 12.7% 8.0%
Primary Hepatic Tumor 4.3% 3.0% 5.2% 4.6% 5.2% 6.8% 4.5% 7.1% 7.9% 9.1%
Metastatic Hepatic Tumor 2.2% 3.3% 3.8% 3.3% 5.7% 5.1% 5.0% 5.1% 4.2% 2.3%
Larynx/Bronchi/Lung 11.3% 12.8% 14.9% 12.5% 16.9% 12.9% 17.1% 13.4% 13.3% 12.5%
Breast/Thyroid 3.6% 4.8% 3.6% 4.1% 2.6% 3.4% 4.3% 2.8% 2.4% 2.3%
Leukemia 1.0% 0.3% 0.5% 1.3% 1.7% 0.8% 0.3% 1.2% - -
Sarcoma (3) 0.2% - 0.7% 0.8% 0.5% 0.4% - 1.2% 0.6% 1.1%
Other 6.0% 6.8% 8.6% 6.6% 6.2% 7.6% 8.6% 8.7% 15.8% 18.2%
Unknown 1.2% 2.3% 0.9% 1.0% 0.7% 0.4% 1.3% 0.4% - 1.1%
Total # of Patients 294 287 322 290 310 338 306 204 139 75


Source: OPTN/SRTR Data as of October 1, 2010.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.